Pandora Endocrine Innovation develops new drugs in the fields of Reproductive Endocrinology, Reproductive Medicine and Endocrine Oncology, based on the Physiology and Pathophysiology of the Female and Male Reproductive System

Everything Should Be Made as Simple as Possible, But Not Simpler. (Albert Einstein)

Pandora Endocrine Innovation (PEI) is based on the three pillars of its name


Pandora, “she who gives and was given all gifts”, is the first human woman in Greek mythology. She is known for opening her box/jar to revenge the stealing of the fire from the gods in heaven, releasing unspecified evils except Hope, left behind in the box. After her creation by the Gods, Pandora received from Hera, the wife of Zeus, the gift of Curiosity, an essential element of PEI.


PEI hopes to create new drugs based on the specific biochemical interaction and mechanism of action through which a drug substance produces its Endocrine Pharmacological Effects in the fields of Women’s Health (WH), Reproductive Medicine (RM) and Reproductive Endocrine Oncology (REO), with special emphasis on the endocrine treatment of advanced breast cancer (BC) and advanced prostate cancer (PC).


For PEI innovation requires an original and verifiable clinical hypothesis that can be subjected to the falsification principle of Karl Popper i.e. to proof that the hypothesis is wrong. The hypothesis must be based on old and new knowledge of the pathophysiology of the medical problem to be solved. The ambition of PEI is to achieve the originality of the Chinese-American architect I.M.Pei (1917-2019) and his Louvre pyramid in Paris is the PEI logo.

About us

PEI was founded by Herjan JT Coelingh Bennink (HCB) on 26 February 2019, with as motto “L’homme n’entreprends rien en vain” (L’Orfeo, Monteverdi). This was exactly 50 years after HCB acquired his MD at the Medical Faculty of the Erasmus University in Rotterdam, the Netherlands.

PEI is managed by HCB as President/CEO, Iman Schultz as Director R&D and Olav Andriesse as General Counsel and Business Development Director (see Management). All other functions are hired on ad hoc need basis.

Business Model

PEI has three areas of interest: Women’s Health (WH with 9 projects), Sublingual Oxytocin (SLOX with 4 projects), Endocrine Treatment of COVID-19 (1 project) and Reproductive Endocrine Oncology (REO with 5 projects). PEI focuses on projects that are suitable for immediate Proof-of-Concept (PoC) studies in the human, with special attention for safety.

All projects are patent protected by PEI or potentially patentable. At present, 11 of the 19 PEI projects have IP protection. After successful PoC and with the help of Pandora’s Hope, a strategical or financial partner is sought for further development.